Skip to main content
. Author manuscript; available in PMC: 2017 Sep 15.
Published in final edited form as: Fertil Steril. 2016 Jul 12;106(4):827–856. doi: 10.1016/j.fertnstert.2016.06.027

Table 3.

BPA and oviduct (experimental studies)

Source Strain Exposure route Time of exposure Doses Time of observation Outcome Ref
Mouse CD-1 Subcutaneous injection GD 1-5 10, 100, 1,000 μg/kg/day 18 months Increased progressive proliferative lesions; remnants of Wolffian ducts (50)
Mouse CD-1 Subcutaneous injection GD 9-16 0.1, 1, 10, 100, 1,000 μg/kg/day 18 months Increased progressive proliferative lesions (49)
Mouse Not indicated Oral gavage GD0.5 – 3.5 200, 400, 600, 800 mg/kg/day GD4 BPA 400 – 800 delayed transfer of embryos from fallopian tubes to uterus (GD4) (51)
Mouse C57BL6 Subcutaneous injection GD 0.5-3.5 0.025, 0.5, 10, 40, 100 mg/kg/day GD3.5 BPA100 retention of embryos and delayed embryo development (52)